Akebia (AKBA) Q2 2026 earnings review
Vafseo Gains Traction, But Auryxia's Generic Cliff Drags Earnings Negative
Akebia's Q2 2026 results highlight a company in a painful transition. While the commercial strategy for Vafseo (vadadustat) is clearly working—sales accelerated 34% sequentially to $21.3 million—the legacy cash cow, Auryxia, collapsed 46% year-over-year. This product shift drove a 21% decline in total revenues and forced profitability to reverse from a $6.1 million net income in Q1 to an $8.9 million net loss in Q2. Management is pushing forward with rare disease pipeline advancements and restructuring the commercial team, but the financial bridge provided by Auryxia is burning faster than Vafseo is currently replacing it.
🐂 Bull Case
Active Vafseo patients jumped 41% sequentially to over 10,500, and prescribers grew 17% to 1,200. The transition to in-center observed dosing implemented in late 2025 is clearly driving sustained volume growth.
The VOICE trial interim analysis hit early stopping criteria, showing statistically significant reductions in mortality and hospitalization vs ESAs. This clinical data provides powerful ammunition to capture market share.
🐻 Bear Case
Auryxia revenue plummeted to $25.5 million in Q2 from $47.2 million a year ago. The company cannot offset this top-line destruction quickly enough, causing total revenues to shrink 21% YoY.
Despite previous management claims of being funded to profitability, operating expenses are climbing (R&D up 28% YoY) while total revenue shrinks, plunging the company back into an $8.9 million net loss.
⚖️ Verdict: ⚪
Neutral. The long-term thesis relies on Vafseo becoming the standard of care, which the VOICE trial data strongly supports. However, the short-term reality is a deteriorating income statement as Auryxia faces devastating generic competition.
Key Themes
Vafseo Volume is Accelerating
After a troubled 2025 launch plagued by adherence issues, Vafseo is finding its footing. Q2 net product revenues of $21.3 million represent a 34% sequential increase over Q1. Crucially, underlying metrics show strong adoption: active patients reached 10,500 (up 41% QoQ), meaning volume is growing faster than revenue, likely due to gross-to-net dynamics or early titrations.
Auryxia Revenue Collapse
The long-feared generic cliff has materialized aggressively. Auryxia sales decelerated sharply, falling 46% YoY to $25.5 million. Management explicitly warned that this contraction will continue due to pricing pressure and generic competition. This rapid decline contradicts the positive narrative around Vafseo's growth, as it pulls total company revenue down by 21%.
VOICE Trial Data Validates Safety Strategy
In a massive win for the company, the planned interim analysis of the 2,116-patient VOICE trial met its predefined stopping criteria. Vafseo dosed three times weekly showed overwhelming statistical evidence of improved safety outcomes compared to standard ESAs (win odds 1.16; p=0.0016), driven by reduced hospitalizations. This explicitly supports Akebia's ultimate goal of displacing ESAs entirely.
Pivot to Rare Kidney Disease Pipeline
With Auryxia fading, Akebia is pushing its future growth pipeline. The company initiated a Phase 2 open-label basket trial evaluating ebribafusp (a next-generation complement inhibitor previously known as AKB-097) across three rare glomerular kidney diseases: IgA nephropathy, lupus nephritis, and C3 glomerulopathy. This expands the narrative beyond anemia, with initial data expected in 2027.
Operating Expenses Outpacing Revenue
Profitability is reversing. Selling, General, and Administrative (SG&A) expenses rose to $28.2 million, and R&D jumped 28% YoY to $14.1 million to support mid-stage assets like praliciguat and ebribafusp. Compounding this was a $1.9 million commercial restructuring charge. Total operating expenses reached $45.0 million—nearly consuming all $49.1 million of total revenue before accounting for the cost of goods sold.
Vafseo COGS Mask True Margin Profile
Akebia noted that Vafseo-related cost of goods sold (COGS) in Q2 continues to be derived from pre-launch inventory, where manufacturing costs were already expensed as R&D prior to U.S. approval. As this zero-cost inventory is depleted, investors should expect gross margins to compress, adding further pressure to the bottom line.
Other KPIs
Decelerating. Down 21% from $62.5 million in the prior year quarter. The $8.0 million YoY gain in Vafseo revenue was entirely overwhelmed by the $21.7 million collapse in Auryxia revenue, reflecting a painful top-line transition.
Down sequentially from $162.6 million at the end of Q1 2026. The return to negative cash flow reflects the net loss of $8.9M. Management plans to refinance their senior secured term loan facility to preserve the balance sheet.
Guidance
Decelerating. Management provided no specific numerical floor for Auryxia, stating only that they expect revenues to continue decreasing compared to 2025 due to generic competition and pricing pressures.
Stable. The company believes existing cash ($155.5M), expected future revenues, and a planned refinancing of its term loan will fund the operating plan for at least 24 months, providing breathing room to ramp Vafseo.
Key Questions
Auryxia Revenue Floor
Auryxia sales fell 46% year-over-year. Is there a baseline level of Auryxia revenue you expect to retain in the face of generic competition, or should we model for a complete phase-out by the end of 2027?
Vafseo Gross Margin Normalization
Vafseo COGS are currently benefiting from zero-cost pre-launch inventory. When do you expect this inventory to be fully depleted, and what is the expected steady-state gross margin profile for Vafseo once that occurs?
Commercial Reorganization Payoff
You recorded a $1.9M restructuring charge this quarter to increase the 'efficiency and effectiveness' of your commercial efforts. What specific structural changes were made, and when will we see the financial benefit of these efficiencies in the SG&A line?
Term Loan Refinancing Terms
Guidance mentions a plan to refinance the senior secured term loan facility. Given the current interest rate environment and the recent flip back to a net loss, what expectations do you have regarding the cost of capital for this refinancing?